Department of Respiratory Medicine, Okayama University Hospital.
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.
Acta Med Okayama. 2022 Oct;76(5):593-596. doi: 10.18926/AMO/64041.
We encountered a woman with re-enlarged axillary lymph nodes during a computed tomography (CT) scan for surveillance of lung adenocarcinoma with axillary lymph node metastasis at the initial diagnosis that had shrunk with standard chemotherapy. We first suspected cancer recurrence and considered a change in the chemotherapeutic regimen. However, after careful history taking regarding the timing of her Coronavirus Disease 2019 (COVID-19) vaccination, and subsequent careful, close follow-up, radiological shrinkage suggested a strictly benign cause. Especially in lung cancer with a medical history of axillary lymph node involvement, cliniciansshould be aware that vaccine-associated lymphadenopathy can mimic cancer recurrence and sometimesprompt serious misjudgment regarding a current treatment course and strategy.
我们在对初始诊断时有腋窝淋巴结转移的肺腺癌进行 CT 扫描以进行监测时,发现一名女性腋窝淋巴结再次肿大,这些淋巴结曾在标准化疗后缩小。我们最初怀疑癌症复发,并考虑改变化疗方案。然而,在仔细询问她 COVID-19 疫苗接种的时间,并进行后续仔细、密切的随访后,影像学上的淋巴结缩小提示这是一个良性病变。特别是在有腋窝淋巴结受累病史的肺癌患者中,临床医生应该意识到,疫苗相关性淋巴结病可能模拟癌症复发,有时会导致对当前治疗方案和策略的严重误判。